Ultra low dose oral contraceptives with less menstrual bleeding

Details Ultra low dose oral contraceptives with less menstrual bleeding Ultra low dose oral contraceptives with less menstrual bleeding

1997-06-23

1999-04-27

Reamer, James H.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514170, 514182, 514843, A61K 3156

Patent

active

058980326

ABSTRACT:
A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.

REFERENCES:
patent: 4390531 (1983-06-01), Edgren
patent: 5098714 (1992-03-01), Wright, et al.
patent: 5108995 (1992-04-01), Casper
patent: 5208225 (1993-05-01), Boissonneault et al.
patent: 5552394 (1996-09-01), Hodgen
patent: 5756490 (1998-05-01), Lachnit et al.
Sheth, et al., Contraception 25:243, 1982.
"A Randomized, Double-Blind Study of Two Combined and Two Progestogen-Only Oral Contraceptives"; Sheth, et al., Contraception; Mar. 1982 vol. 25., No. 3; pp. 243-253.

Affiliated with

Also associated with

Rating

Ultra low dose oral contraceptives with less menstrual bleeding does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ultra low dose oral contraceptives with less menstrual bleeding , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ultra low dose oral contraceptives with less menstrual bleeding will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-685729